Work Group on Major Depressive Disorder.
Practice Guideline for the Treatment of Patients with Major
American Psychiatric Association,
National Collaborating Centre for Mental Health.
Depression: The Treatment and Management of Depression in Adults
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und
S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression
Langfassung [S3 Guideline/National Guideline Unipolar Depressive
Disorder] (version 1.3.): 264.
Ärztliches Zentrum für Qualität in der
Ioannidis, JP, Evans, SJ, Gotzsche, PC, O'Neill, RT, Altman, DG, Schulz, K, et al. Better reporting of harms in randomized
trials: an extension of the CONSORT statement.
Ann Intern Med
2004; 141: 781–8.
Kirsch, I. The Emperor's New Drugs: Exploding the Antidepressant
Moncrieff, J. Are antidepressants overrated? A review of
methodological problems in antidepressant trials.
J Nerv Ment Dis
2001; 189: 288–95.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and
its influence on apparent efficacy. N Engl J
2008; 358: 252–60.
Greenberg, RP, Bornstein, RF, Zborowski, MJ, Fisher, S, Greenberg, MD. A meta-analysis of fluoxetine outcome in the
treatment of depression. J Nerv Ment Dis
1994; 182: 547–51.
Hamilton, M. A rating scale for depression.
J Neurol Neurosurg Psychiatry
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to
change. Br J Psychiatry
1979; 134: 382–9.
Higgins, JPT, Deeks, JJ. Selecting studies and collecting
data. In Cochrane Handbook for Systematic Reviews
of Interventions (eds Higgins, JPT, Green, S): 151–85. Wiley,
Higgins, JPT, Deeks, JJ. Assessing risk of bias in included
studies. In Cochrane Handbook for Systematic
Reviews of Interventions (eds Higgins, JPT, Green, S): 187–235.
DerSimonian, R, Laird, N. Meta-analysis in clinical trials.
Control Clin Trials
1986; 7: 177–88.
Lipsey, MW, Wilson, DB. Practical Meta-Analysis.
Cusin, C, Yang, H, Yeung, A, Fava, M. Rating scales for depression. In
Handbook of Clinical Rating Scales and Assessment in Psychiatry
and Mental Health (eds Baer, L, Blais, MA): 7–36. Humana
Gartlehner, G, Hansen, RA, Thieda, P, DeVeaugh-Geiss, AM, Gaynes, BN, Krebs, EE, et al. Comparative Effectiveness of Second-Generation
Antidepressants in the Pharmacologic Treatment of Adult Depression.
Comparative Effectiveness Review No. 7.
Agency for Healthcare Research and Quality,
Papakostas, GI, Fava, M. Does the probability of receiving placebo influence
clinical trial outcome? A meta-regression of double-blind, randomized
clinical trials in MDD. Eur
Baron, RM, Kenny, DA. The moderator-mediator variable distinction in
social psychological research: conceptual, strategic, and statistical
considerations. J Pers Soc Psychol
1986; 51: 1173–82.
MacKinnon, DP, Fairchild, AJ, Fritz, MS. Mediation analysis. Annu Rev
Sobel, ME. Asymptotic confidence intervals for indirect effects
in structural equations models. In Sociological
Methodology (ed. Leinhart, S): 290–312.
Sobel, ME. Some new results on indirect effects and their
standard errors in covariance structure models. In
Sociological Methodology 1986 (ed. Tuma, N): 159–86. American Sociological
Aroian, LA. The probability function of the product of two
normally distributed variables. Ann Math
1944; 18: 265–71.
MacKinnon, DP, Lockwood, CM, Hoffman, JM, West, SG, Sheets, V. A comparison of methods to test mediation and other
intervening variable effects. Psychol
Barbui, C, Furukawa, TA, Cipriani, A. Effectiveness of paroxetine in the treatment of
acute major depression in adults: a systematic re-examination of
published and unpublished data from randomized trials.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a
meta-analysis of data submitted to the Food and Drug
Administration. PLoS Med
2008; 5: e45.
Baethge, C, Asall, OP, Baldessarini, RJ. Systematic review of blinding assessment in
randomized controlled trials in schizophrenia and affective disorders
2000–2010. Psychother Psychosom
2013; 82: 152–60.
Bello, S, Moustgaard, H, Hrobjartsson, A. The risk of unblinding was infrequently and
incompletely reported in 300 randomized clinical trial
publications. J Clin Epidemiol
2014; 67: 1059–69.
Moher, D, Hopewell, S, Schulz, KF, Montori, V, Gotzsche, PC, Devereaux, PJ, et al. CONSORT 2010 explanation and elaboration:
updated guidelines for reporting parallel group randomised
Rief, W, Nestoriuc, Y, von Lilienfeld-Toal, A, Dogan, I, Schreiber, F, Hofmann, SG, et al. Differences in adverse effect reporting in
placebo groups in SSRI and tricyclic antidepressant trials: a systematic
review and meta-analysis. Drug Saf
2009; 32: 1041–56.
Shedden Mora, M, Nestoriuc, Y, Rief, W. Lessons learned from placebo groups in
antidepressant trials. Philos Trans R Soc Lond B
2011; 366: 1879–88.
Rief, W, Avorn, J, Barsky, AJ. Medication-attributed adverse effects in placebo
groups: implications for assessment of adverse effects.
Arch Intern Med
2006; 166: 155–60.
Colloca, L, Benedetti, F. How prior experience shapes placebo
2006; 124: 126–33.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC, et al. Antidepressant drug effects and depression
severity: a patient-level meta-analysis.
Gibbons, RD, Hur, K, Brown, CH, Davis, JM, Mann, JJ. Benefits from antidepressants: synthesis of 6-week
patient-level outcomes from double-blind placebo-controlled randomized
trials of fluoxetine and venlafaxine. Arch Gen
2012; 69: 572–9.